Cancer drug development using glucose metabolism radiopharmaceuticals

Current Pharmaceutical Design

Volumn 15, Issue 9, 2009, Pages 983-987

  Sun, Y Y ^a   Chen, Yue ^a  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

18F FDG; 188Re; 99mTc; Imaging; Positron emission tomography; Radiopharmaceutical; SPECT

Indexed keywords

DEOXYGLUCOSE CL 34M; ETHYLENEDICYSTEINEGLUCOSAMINE TC 99M; FLUORODEOXYGLUCOSE F 18; FLUORODEOXYGLUCOSE MALEIMIDEHEXYLOXIME F 18; GLUCOSAMINE TC 99M; GLUCOSE; GLUCOSE TRANSPORTER; MERTIATIDE DEOXYGLUCOSE TC 99M; PENTETIC ACID DEOXYGLUCOSE RE 188; PENTETIC ACID DEOXYGLUCOSE TC 99M; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; SACCHARIC ACID TC 99M; TECHNETIUM 99M; THIOGLUCOSE TC 99M; TRACER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT;

CANCER RESEARCH; CANCER STAGING; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RESEARCH; DRUG RESPONSE; DRUG STRUCTURE; DRUG UPTAKE; FOLLOW UP; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; ANIMAL; ARTICLE; DRUG DESIGN; METABOLISM; METHODOLOGY; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 65549132039     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582048     Document Type: Review

References (34)

1. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II. Ann Nucl Med 2008; 22(8): 699-705.
2. Maldonado A, González-Alenda FJ, Alonso M, Sierra JM. PET-CT in clinical oncology. Clin Transl Oncol 2007; 9(8): 494-505.
3. Gillham CM, Reynolds J, Hollywood D. Predicting the response of localized oesophageal cancer to neo-adjuvant chemoradiation. World J Surg Oncol 2007; 5: 97.
4. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002; 43(2): 173-80.
5. Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 2002; 29(4): 443-53.
6. 18F]-2-Deoxy-D-Glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II. Acta Radiol 2008; 31: 1-10.
7. 18F-labeling of peptides. Bioconjug Chem 2008; 19(6): 1202-10.
8. 99mTc EC-DG targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology 2003; 226(2): 465-73.
9. Yang DJ, Kim EE. Tracer development and hybrid imaging. Eur J Nucl Med Mol Imaging 2005; 32(9): 1001-2.
10. 99mTc]-DTPA-DG) as a potential imaging modality for tumors. Appl Radiat Isot 2006; 64(3): 342-7.
11. 99mTc-DTPA-deoxyglucose: an experimental study. Cancer Biother Radiopharm 2007; 22(3): 403-5.
12. Gillies RJ, Gatenby RA. Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr 2007; 39(3): 251-7.
13. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. Neoplasia 2005; 7(1): 1-6.
14. Mendcz LE, Manci N, Cantuarin G, Gomez-Marin O, Penalver M, Braunschweiger P, et a1. Expression of glucose transporter-1 in cervical cancer and its precursors. Gynecol Oncol 2002; 86(2): 138-43.
15. Younes M, Juarez D, Lechago LV, Lerner SP. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anti Cancer Res 2001; 21(1a): 575-8.
16. Deantonio L, Beldi D, Gambaro G, Loi G, Brambilla M, Inglese E, et al. FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol 2008; 3(1): 29.
17. Fülöp N, Zhang Z, Marchase RB, Chatham JC. Glucosamine cardioprotection in perfused rat hearts associated with increased O-linked N-acetylglucosamine protein modification and altered p38 activation. Am J Physiol Heart Circ Physiol 2007; 292(5): H2227-36.
18. Dehennaut V, Lefebvre T, Sellier C, Leroy Y, Gross B, Walker S, et al. O-linked N-acetylglucosaminyltransferase inhibition prevents G2/M transition in Xenopus laevis oocytes. J Biol Chem 2007; 282(17): 12527-36.
19. Chen X, Li L, Liu F, Liu B. Synthesis and biological evaluation of technetium-99m-labeled deoxyglucose derivatives as imaging agents for tumor. Bioorg Med Chem Lett 2006; 16 (21): 5503-6
20. 99mTc]-TA-DG) As a Tumor Imaging Agent. Iran J Nucl Med 2007; 15(2): 43-8.
21. 99mTechnetium carbohydrate conjugates as potential agents in molecular imaging. Chem Commun 2008; 7(41): 5077-91.
22. 186Re). Bioconjug Chem 2006; 17(5): 1321-9.
23. m-labelled 5-thio-D-glucose. Nucl Med Commun 1999; 20(11): 1055-8.
24. 99m glucarate for the necrotic myocardium: in vivo and invitro assessment. J Nucl Cardiol 1997; 4(4): 283-90.
25. Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 2008; 51(15): 4504-17.
26. 188Re-anti-CD20 in patients with non-Hodgkin's lymphoma: preliminary experience. Arch Med Res 2008; 9(1): 100-9.
27. 188Re-DTPA-DG in MCF-7 breast carcinoma and A549 pulmonary carcinoma cells. Cancer Biother Radiopharm 2007; 22(4): 543-50.
28. 188Re-DTPA-deoxyglucose in MCF-7 tumor-bearing mice. Cancer Biother Radiopharm 2007; 22(3): 400-2.
29. 188Re-DTPA-DG-treatment of human breast cancer-bearing nude mice. Zhonghua Zhong Liu Za Zhi 2007; 29(8): 589-90.
30. 186Re(I) tricarbonyl complexes of N-(2′-Hydroxybenzyl)-2-amino-2-deoxy-D-glucose. Bioconjug Chem 2004; 15(4): 923-6.
31. 18F-FDG injection. Appl Radiat Isot 2008; 66(12): 1905-9.
32. Bauer M, Wagner CC, Langer O. Microdosing studies in humans: the role of positron emission tomography. Drugs RD 2008; 9(2): 73-81.
33. Neglia D, Rimoldi O, Kaufmann PA, Camici PG. Radionuclide PET and PET/CT in coronary artery disease. Curr Pharm Des 2008; 14(18): 1798-814.
34. Wagner CC, Muller M, Lappin G, Langer O. Positron emission tomography for use in microdosing studies. Curr Opin Drug Discov Devel 2008; 11(1): 104-10.